Chemotherapy-induced Nausea and Vomiting Drugs Market Size, Trends, Shares, and Forecast - 2031

Chemotherapy-induced Nausea and Vomiting Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy type (Serotonin receptor antagonists, NK1 receptor antagonists, Dopamine antagonists, Benzodiazepines, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031
  • Report Date : Apr 2026
  • Report Code : TIPRE00016843
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Chemotherapy-induced Nausea and Vomiting Drugs Market Size, Trends, Shares, and Forecast - 2031
Report Date: Apr 2026   |   Report Code: TIPRE00016843
Buy Now
Page Updated: Sep 2025

MARKET INTRODUCTION


Chemotherapy-induced nausea and vomiting (CINV) is type of nausea and vomiting caused by cancer drugs dosage. Cancer patient may experience nausea and vomiting within 24 hours (acute type) or after 24 hours (delayed type) of chemotherapy medication. Chemotherapy-induced nausea and vomiting leads to the deferment or refusal of therapeutic chemotherapy treatment for cancer.

MARKET DYNAMICS


Factors driving growth of Chemotherapy-induced Nausea and Vomiting Drugs market during the forecast period are the increasing number of government initiatives in oncology research, rising number of oncology research and development activities, growing incidence of cancer cases, rising adoption of chemotherapy and combination therapy. These are the major factors driving the Chemotherapy-induced Nausea and Vomiting Drugs market.

Customize This Report To Suit Your Requirement

Get FREE CUSTOMIZATION

Chemotherapy-induced Nausea and Vomiting Drugs Market: Strategic Insights

chemotherapy-induced-nausea-and-vomiting-drugs-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

The "Global Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis to 2031" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of Chemotherapy-induced Nausea and Vomiting Drugs Market with detailed market segmentation by therapy type and geography. The global Chemotherapy-induced Nausea and Vomiting Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Chemotherapy-induced Nausea and Vomiting Drugs Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION


The global Chemotherapy-induced Nausea and Vomiting Drugs Market is segmented on basis of therapy type. Based on therapy type, the global Chemotherapy-induced Nausea and Vomiting Drugs Market is segmented into dopamine antagonists, serotonin receptor antagonists, benzodiazepines, and neurokinin NK1 receptor antagonist.

Chemotherapy-induced Nausea and Vomiting Drugs Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Therapy type
  • Serotonin receptor antagonists
  • NK1 receptor antagonists
  • Dopamine antagonists
  • Benzodiazepines
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • GlaxoSmithKline plc
  • Merck and Co., Inc
  • Teva Pharmaceuticals
  • Heron Therapeutics, Inc.
  • F. Hoffmann-La Roche AG
  • Tesaro, Inc.
  • Acacia Pharma
  • Baxter international Inc.
  • Lee's Pharmaceutical Holdings
  • Mundipharma International limited

Chemotherapy-induced Nausea and Vomiting Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The Chemotherapy-induced Nausea and Vomiting Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

chemotherapy-induced-nausea-and-vomiting-drugs-market-cagr

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Chemotherapy-induced Nausea and Vomiting Drugs Market based on various segments. It also provides market size and forecast estimates from year 2021 to2031with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Chemotherapy-induced Nausea and Vomiting Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Chemotherapy-induced Nausea and Vomiting Drugs Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Chemotherapy-induced Nausea and Vomiting Drugs Market in these regions.

MARKET PLAYERS


The reports cover key developments in the Chemotherapy-induced Nausea and Vomiting Drugs Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Chemotherapy-induced Nausea and Vomiting Drugs Market are anticipated to lucrative growth opportunities in the future with the rising demand for activated carbon maskin the global market. Below mentioned is the list of fewcompanies engaged in the Chemotherapy-induced Nausea and Vomiting Drugs Market.

The report also includes the profiles of key Chemotherapy-induced Nausea and Vomiting Drugs Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  •  GlaxoSmithKline plc
  •  Merck and Co., Inc
  •  Teva Pharmaceuticals
  •  Heron Therapeutics, Inc.
  •  F. Hoffmann-La Roche AG
  •  Tesaro, Inc.
  •  Acacia Pharma
  •  Baxter international Inc.
  •  Lee's Pharmaceutical Holdings
  •  Mundipharma International limited

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
GDPR
CCPA